High Cardiovascular RiskPhase 2KARDIA-3NCT06272487
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
A Phase 2 study testing Zilebesiran in people with High Cardiovascular Risk and Hypertension, run by Alnylam Pharmaceuticals at 195 sites in 6 countries.
Trial summary
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- High Cardiovascular Risk, Hypertension
- What is being tested?
- Zilebesiran
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 375 participants
- Where
- 195 sitesin 6 countries
- Study dates
- 29 Feb 2024to 1 Dec 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min/1.73m^2
- Mean seated office SBP ≥140 mmHg and ≤170 mmHg
- 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
- Must be on stable therapy with 2 to 4 classes of antihypertensive medications
Who cannot join
- Secondary hypertension
- Orthostatic hypotension
- Proteinuria >3 g/day
- Serum potassium >4.8 milliequivalents per liter (mEq/L)
Trial locations and contacts
195 sites in 6 countries.
195 sites in 6 countries
United States139 sites
Clinical Trial Site
Acworth, Georgia, 30101
Clinical Trial Site
Albuquerque, New Mexico, 87109
Clinical Trial Site
Alexander City, Alabama, 35010
Clinical Trial Site
Atlanta, Georgia, 30322
Clinical Trial Site
Austin, Texas, 78744
Clinical Trial Site
Berlin, New Jersey, 08009
Clinical Trial Site
Bethlehem, Pennsylvania, 18017
Clinical Trial Site
Beverly Hills, California, 90211
Clinical Trial Site
Boise, Idaho, 83706
Clinical Trial Site
Boston, Massachusetts, 02114
Clinical Trial Site
Burke, Virginia, 22015
Clinical Trial Site
Burlington, Vermont, 05401
Clinical Trial Site
Charlotte, North Carolina, 28287
Clinical Trial Site
Chattanooga, Tennessee, 37404
Clinical Trial Site
Chicago, Illinois, 60602
Clinical Trial Site
Clearwater, Florida, 33756
Clinical Trial Site
Cleveland, Ohio, 44106
Clinical Trial Site
Colorado Springs, Colorado, 80918
Clinical Trial Site
Columbus, Georgia, 31904
Clinical Trial Site
Columbus, Mississippi, 39705
Clinical Trial Site
Coppell, Texas, 75019
Clinical Trial Site
Coral Gables, Florida, 33134
Clinical Trial Site
Covina, California, 91723
Clinical Trial Site
Creve Coeur, Missouri, 63141
Clinical Trial Site
Dallas, Texas, 75230
Clinical Trial Site
Dallas, Texas, 75234
Clinical Trial Site
Daphne, Alabama, 36526
Clinical Trial Site
Daytona Beach, Florida, 32117
Clinical Trial Site
Denver, Colorado, 80210
Clinical Trial Site
Denver, Colorado, 80230
Clinical Trial Site
Douglasville, Georgia, 30134
Clinical Trial Site
Durham, North Carolina, 27704
Clinical Trial Site
Durham, North Carolina, 27713
Clinical Trial Site
East Providence, Rhode Island, 02914
Clinical Trial Site
El Dorado, Kansas, 67042
Clinical Trial Site
El Paso, Texas, 79925
Clinical Trial Site
El Paso, Texas, 79935
Clinical Trial Site
Elkhart, Indiana, 46514
Clinical Trial Site
Encinitas, California, 92024
Clinical Trial Site
Evansville, Indiana, 47714
Clinical Trial Site
Flint, Michigan, 48504
Clinical Trial Site
Foley, Alabama, 36535
Clinical Trial Site
Fort Myers, Florida, 33912
Clinical Trial Site
Gainesville, Georgia, 30501
Clinical Trial Site
Garden Grove, California, 92844
Clinical Trial Site
Germantown, Tennessee, 38138
Clinical Trial Site
Gilbert, Arizona, 85297
Clinical Trial Site
Greensboro, North Carolina, 27401
Clinical Trial Site
Greenville, North Carolina, 27834
Clinical Trial Site
Hartford, Connecticut, 06112
Clinical Trial Site
Hollywood, Florida, 33021
Clinical Trial Site
Houston, Texas, 77002
Clinical Trial Site
Houston, Texas, 77024
Clinical Trial Site
Houston, Texas, 77054
Clinical Trial Site
Houston, Texas, 77081
Clinical Trial Site
Houston, Texas, 77099
Clinical Trial Site
Huntington Beach, California, 92647
Clinical Trial Site
Huntsville, Alabama, 35801
Clinical Trial Site
Huntsville, Alabama, 35805
Clinical Trial Site
Jacksonville, Florida, 32204
Clinical Trial Site
Jacksonville, Florida, 32209
Clinical Trial Site
Jacksonville, Florida, 32256
Clinical Trial Site
Jensen Beach, Florida, 34957
Clinical Trial Site
Kalispell, Montana, 59901
Clinical Trial Site
Knoxville, Tennessee, 37909
Clinical Trial Site
Knoxville, Tennessee, 37923
Clinical Trial Site
Lake City, Florida, 32055
Clinical Trial Site
Langhorne, Pennsylvania, 19047
Clinical Trial Site
Las Vegas, Nevada, 89121
Clinical Trial Site
Lincoln, Nebraska, 68510
Clinical Trial Site
Los Angeles, California, 90022
Clinical Trial Site
Los Angeles, California, 90057
Clinical Trial Site
Magnolia, Texas, 77355
Clinical Trial Site
Manassas, Virginia, 20109
Clinical Trial Site
Marion, Ohio, 43302
Clinical Trial Site
Memphis, Tennessee, 38119
Clinical Trial Site
Miami, Florida, 33126
Clinical Trial Site
Miami, Florida, 33135
Clinical Trial Site
Miami, Florida, 33137
Clinical Trial Site
Miami, Florida, 33144
Clinical Trial Site
Miami, Florida, 33155
Clinical Trial Site
Miami, Florida, 33176
Clinical Trial Site
Middlebury, Connecticut, 06762
Clinical Trial Site
Minneapolis, Minnesota, 55404
Clinical Trial Site
Miramar, Florida, 33027
Clinical Trial Site
Monroe, Louisiana, 71201
Clinical Trial Site
Monroe, North Carolina, 28112
Clinical Trial Site
Montgomery, Alabama, 36117
Clinical Trial Site
Myrtle Beach, South Carolina, 29572
Clinical Trial Site
New Orleans, Louisiana, 70119
Clinical Trial Site
New York, New York, 10017
Clinical Trial Site
Newport, Pennsylvania, 17074
Clinical Trial Site
Newton, Kansas, 67114
Clinical Trial Site
Norfolk, Virginia, 23504
Clinical Trial Site
Norman, Oklahoma, 73072
Clinical Trial Site
Northridge, California, 91324
Clinical Trial Site
Northridge, California, 91325
Clinical Trial Site
Oklahoma City, Oklahoma, 73102
Clinical Trial Site
Omaha, Nebraska, 68114
Clinical Trial Site
Orlando, Florida, 32801
Clinical Trial Site
Owensboro, Kentucky, 42303
Clinical Trial Site
Pasadena, California, 91105
Clinical Trial Site
Philadelphia, Pennsylvania, 19114
Clinical Trial Site
Phoenix, Arizona, 85028
Clinical Trial Site
Portsmouth, New Hampshire, 03801
Clinical Trial Site
Raleigh, North Carolina, 27609
Clinical Trial Site
Rapid City, South Dakota, 57701
Clinical Trial Site
Richfield, Minnesota, 55423
Clinical Trial Site
Richmond, Indiana, 47374
Clinical Trial Site
San Antonio, Texas, 78229
Clinical Trial Site
San Antonio, Texas, 78240
Clinical Trial Site
San Diego, California, 92108
Clinical Trial Site
San Diego, California, 92111
Clinical Trial Site
San Dimas, California, 91773
Clinical Trial Site
Savannah, Georgia, 31406
Clinical Trial Site
Shelby, Michigan, 48315
Clinical Trial Site
Shenandoah, Texas, 77384
Clinical Trial Site
Sherman, Texas, 75092
Clinical Trial Site
Simi Valley, California, 93065
Clinical Trial Site
Stephenville, Texas, 76401
Clinical Trial Site
Sun City, Arizona, 85351
Clinical Trial Site
Tempe, Arizona, 85281
Clinical Trial Site
The Villages, Florida, 32162
Clinical Trial Site
Thomasville, Georgia, 31792
Clinical Trial Site
Tomball, Texas, 77375
Clinical Trial Site
Tucson, Arizona, 85741
Clinical Trial Site
Tupelo, Mississippi, 38801
Clinical Trial Site
Vacaville, California, 95687
Clinical Trial Site
Van Nuys, California, 91405
Clinical Trial Site
Washington D.C., District of Columbia, 20009
Clinical Trial Site
Waterbury, Connecticut, 06708
Clinical Trial Site
West Allis, Wisconsin, 53227
Clinical Trial Site
West Hills, California, 91307
Clinical Trial Site
West Springfield, Massachusetts, 01089
Clinical Trial Site
Wichita, Kansas, 67207
Clinical Trial Site
Wilmington, North Carolina, 28403
Clinical Trial Site
Winston-Salem, North Carolina, 27103
Clinical Trial Site
Winter Haven, Florida, 33880
Clinical Trial Site
Ypsilanti, Michigan, 48197
United Kingdom24 sites
Clinical Trial Site
Bellshill, ML4 3NJ
Clinical Trial Site
Birmingham, B15 2SQ
Clinical Trial Site
Bristol, BS2 8HW
Clinical Trial Site
Canterbury, CT1 3NG
Clinical Trial Site
Cardiff, CF15 9SS
Clinical Trial Site
Carshalton, SM5 1AA
Clinical Trial Site
Chesterfield, S40 4AA
Clinical Trial Site
Chorley, PR7 7NA
Clinical Trial Site
Fowey, PL23 1DT
Clinical Trial Site
Glasgow, G20 7BE
Clinical Trial Site
Glasgow, G51 4TF
Clinical Trial Site
Hexham, NE46 1QJ
Clinical Trial Site
Leicester, LE5 4PW
Clinical Trial Site
Liskeard, PL14 3XA
Clinical Trial Site
Liverpool, L22 0LG
Clinical Trial Site
London, EC1A 7BE
Clinical Trial Site
London, SE1 1YR
Clinical Trial Site
London, SW17 0QT
Clinical Trial Site
Luton, LU4 0DZ
Clinical Trial Site
Manchester, M15 6SE
Clinical Trial Site
Newquay, TR7 1RU
Clinical Trial Site
Pickering, YO18 8BL
Clinical Trial Site
Plymouth, PL5 3JB
Clinical Trial Site
Torpoint, PL11 2TB
Canada15 sites
Clinical Trial Site
Brampton, L6T 0G1
Clinical Trial Site
Chicoutimi, G7H 7K9
Clinical Trial Site
Greenfield Park, J4V 2G8
Clinical Trial Site
Montreal, H4J 1C5
Clinical Trial Site
Montreal, H4N 2W2
Clinical Trial Site
Québec, G1W 4R4
Clinical Trial Site
Québec, G1V 4T3
Clinical Trial Site
Sainte-Foy, G1V 4G5
Clinical Trial Site
Sarnia, N7T 4X3
Clinical Trial Site
Toronto, M3J 0K2
Clinical Trial Site
Toronto, M4P 1E4
Clinical Trial Site
Toronto, M5B 1W8
Clinical Trial Site
Trois-Rivières, G9A 4P3
Clinical Trial Site
Waterloo, N2T 0C1
Clinical Trial Site
Winnipeg, R2V 3M3
Australia11 sites
Clinical Trial Site
Blacktown, 2148
Clinical Trial Site
Brookvale, 2100
Clinical Trial Site
Bruce, 2617
Clinical Trial Site
Concord, 2139
Clinical Trial Site
Garran, 2605
Clinical Trial Site
Kanwal, 2259
Clinical Trial Site
Kogarah, 2217
Clinical Trial Site
Perth, 6000
Clinical Trial Site
Sippy Downs, 4556
Clinical Trial Site
St Leonards, 2065
Clinical Trial Site
Tarragindi, 4121
Switzerland4 sites
Clinical Trial Site
Basel, 4031
Clinical Trial Site
Geneva, 1205
Clinical Trial Site
Lausanne, 1005
Clinical Trial Site
Lucerne, 6000
Puerto Rico2 sites
Clinical Trial Site
Ponce, 00716
Clinical Trial Site
Toa Baja, 00949
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Conditions
- High Cardiovascular Risk, Hypertension
- Being tested
- Zilebesiran, Placebo
- Keywords
- High blood pressure, Hypertension, siRNA, Angiotensinogen, AGT, Cardiovascular disease, Chronic kidney disease, Uncontrolled hypertension
- Medical subject headings
- Hypertension, Cardiovascular Diseases, Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZilebesiranDrug
Also called ALN-AGT01
Zilebesiran administered by subcutaneous (SC) injection
PlaceboDrug
Placebo administered by SC injection
| Study group | Role | What they receive |
|---|---|---|
| Zilebesiran | Experimental | Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period. Receives: Drug: Zilebesiran |
| Placebo | Placebo comparator | Participants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP)
Measured: Baseline and Month 3
Secondary outcomes (9)
Change from Baseline at Month 3 in 24-Hour Mean SBP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
Measured: Baseline and Month 3
Change from Baseline at Month 6 in Mean Seated Office SBP
Measured: Baseline and Month 6
Change from Baseline at Month 6 in 24-Hour Mean SBP Assessed by ABPM
Measured: Baseline and Month 6
Proportion of Patients with Mean Seated Office SBP <140 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6
Measured: Month 6
Proportion of Patients with 24-hour Mean SBP assessed by ABPM <130 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6
Measured: Month 6
Change from Baseline at Month 3 and Month 6 in Daytime and Nighttime Mean SBP and Diastolic Blood Pressure (DBP) assessed by ABPM
Measured: Baseline and Months 3 and 6
Change from Baseline at Month 3 and Month 6 in Mean Seated Office DBP
Measured: Baseline and Months 3 and 6
Change from Baseline at Month 3 and Month 6 in 24-hour Mean DBP Assessed by ABPM
Measured: Baseline and Months 3 and 6
Change from Baseline Over Time in Serum Angiotensinogen (AGT)
Measured: Baseline through Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2024
- Study start29 Feb 2024
- Primary completion19 Jun 2025
- Study completion1 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for High Cardiovascular RiskStudies of the same condition, open and under way.
- More trials run by Alnylam PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 375 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alnylam Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Alnylam Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06272487
- Sponsor's protocol ID
- ALN-AGT01-007
- Acronym
- KARDIA-3
- Status last verified
- Feb 2026
- First submitted
- 15 Feb 2024
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications
- ClinicalTrials.gov ID
- NCT06272487
- Acronym / sponsor ID
- KARDIA-3 / ALN-AGT01-007
- Conditions
- High Cardiovascular Risk, Hypertension
- Keywords
- High blood pressure, Hypertension, siRNA, Angiotensinogen, AGT, Cardiovascular disease, Chronic kidney disease, Uncontrolled hypertension
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 375 participants (actual)
- Lead sponsor
- Alnylam PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 29 Feb 2024 (actual)
- Primary completion
- 19 Jun 2025 (actual)
- Study completion
- 1 Dec 2025 (actual)
- First posted
- 22 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Zilebesiran | Experimental | Drug: ZilebesiranParticipants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min/1.73m^2
- Mean seated office SBP ≥140 mmHg and ≤170 mmHg
- 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
- Must be on stable therapy with 2 to 4 classes of antihypertensive medications
Key exclusion criteria (4 listed)
- Secondary hypertension
- Orthostatic hypotension
- Proteinuria >3 g/day
- Serum potassium >4.8 milliequivalents per liter (mEq/L)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZilebesiranAlso: ALN-AGT01Zilebesiran administered by subcutaneous (SC) injection | Drug | Zilebesiran |
| PlaceboPlacebo administered by SC injection | Drug | Placebo |
Primary outcome
Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP)
Time frame: Baseline and Month 3
9 secondary outcomes
Change from Baseline at Month 3 in 24-Hour Mean SBP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
Time frame: Baseline and Month 3
Change from Baseline at Month 6 in Mean Seated Office SBP
Time frame: Baseline and Month 6
Change from Baseline at Month 6 in 24-Hour Mean SBP Assessed by ABPM
Time frame: Baseline and Month 6
Proportion of Patients with Mean Seated Office SBP <140 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6
Time frame: Month 6
Proportion of Patients with 24-hour Mean SBP assessed by ABPM <130 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6
Time frame: Month 6
Change from Baseline at Month 3 and Month 6 in Daytime and Nighttime Mean SBP and Diastolic Blood Pressure (DBP) assessed by ABPM
Time frame: Baseline and Months 3 and 6
Change from Baseline at Month 3 and Month 6 in Mean Seated Office DBP
Time frame: Baseline and Months 3 and 6
Change from Baseline at Month 3 and Month 6 in 24-hour Mean DBP Assessed by ABPM
Time frame: Baseline and Months 3 and 6
Change from Baseline Over Time in Serum Angiotensinogen (AGT)
Time frame: Baseline through Month 6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: Yes. Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Related trials for High Cardiovascular Risk
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Recruiting
Decision Support for Chemoprevention
Breast Cancer
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruitingPhase 2
The CARDIOPROTECT Trial
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
RecruitingPhase 3
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Alnylam Pharmaceuticals
195 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Zilebesiran in people with High Cardiovascular Risk and Hypertension, run by Alnylam Pharmaceuticals at 195 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 195 sites in United States, United Kingdom, Canada, Australia, Switzerland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP) (time frame: Baseline and Month 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.